Lauge Schäffer

Title: Lauge Schäffer: Innovator in Peptide Therapeutics

Introduction

Lauge Schäffer is a notable inventor based in Copenhagen, Denmark. He has made significant contributions to the field of peptide therapeutics, particularly in the development of insulin and IGF-1 receptor agonists and antagonists. His innovative work has the potential to impact therapeutic approaches for various health conditions.

Latest Patents

Lauge Schäffer holds a patent for "Insulin and IGF-1 receptor agonists and antagonists." This patent discloses peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity. The invention identifies at least two different binding sites present on these receptors, which selectively bind the peptides. As agonists, certain peptides may be useful for developing therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.

Career Highlights

Throughout his career, Lauge has focused on advancing the understanding of peptide interactions with insulin and IGF-1 receptors. His work has led to the identification of novel peptide sequences that could revolutionize treatment options in endocrinology and related fields.

Collaborations

Lauge has collaborated with talented individuals such as Renuka Pillutla and Renee Brissette. Their combined expertise has contributed to the success of his innovative projects.

Conclusion

Lauge Schäffer's contributions to peptide therapeutics exemplify the importance of innovation in medicine. His patent on insulin and IGF-1 receptor modulators showcases the potential for new therapeutic avenues.